Answers are grounded in this paper and cite their sources.
A prospective study was conducted in the Clinic Hospital of Obstetrics and Gynecology "Dr. I.A. Sbârcea" Brașov, which included hospitalized pregnant women diagnosed with COVID-19 from January 1, 2020, to March 8, 2022. The study aimed to evaluate the influence of SARS-CoV-2 on the coagulation status, the blood levels of coagulation parameters, and the presence of disseminated intravascular coagulation in pregnant women with COVID-19. To analyze the coagulation status of the pregnant women we used the following parameters: Fibrinogen level, INR, D-dimer test, and the presence of disseminated intravascular coagulation. Following the study, we concluded that the occurrence of coagulation disorders in pregnant women is related to the severity of the SARS-CoV 2. LMWH administration generally improved the prognosis of pregnancy-associated COVID-19 and mostly prevented the occurrence of severe thromboembolic complications such as disseminated intravascular coagulation or deep venous thrombosis.
No takes yet. Share an insight, caveat, or question.
CASAP et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: